Excell Partners

Still cutting its teeth, Traverse set for stellar 2017

By GREGORY ZELLER // First, healthy teeth for dogs … then a cancer cure for the world? Financially and otherwise, Traverse Biosciences enjoyed a strong 2016 – but it may ultimately pale compared to what’s shaping up as a potentially enormous 2017 for the Stony Brook biotech and its flagship pharmaceutical. Fueled primarily by a $1.32 million Phase II Small Business Technology Transfer award granted by the National Institutes of Health in August to the…


Traverse Biosciences lands key seed investment

By GREGORY ZELLER // A critical seed investment will help Traverse Biosciences commercialize pharmaceutical candidates licensed from the SUNY Research Foundation. The circa-2013 Stony Brook-based biotech has secured $500,000 in convertible debt financing in a round led by Excell Partners, a Rochester-based venture capital fund partial to early-stage, high-tech startups. The SUNY Research Foundation added an undisclosed investment to Excell Partner’s $100,000 stake, while a collection of 10 accredited angel investors – “almost exclusively from…